title: Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate carcinoma.
abstract: OBJECTIVE
  To evaluate serum levels of the carboxy-terminal propeptide of type I procollagen (PICP) and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) as possible markers of bone metastases in patients with prostate carcinoma (PCA) patients.
  
  
  METHODS
  Levels of PICP and ICTP were measured by radioimmunoassay of serum from 29 patients with benign prostatic hyperplasia (BPH), 17 patients with PCA without bone metastases and 29 patients with PCA and bone metastases.
  
  
  RESULTS
  Serum levels of PICP in patients with PCA and bone metastases (mean +/- SD 304.3 +/- 365.9 ng/ml) were significantly higher than those in patients with BPH (95.6 +/- 27.1 ng/ml) and in patients with PCA without bone metastases (111.1 +/- 44.6 ng/ml). No significant difference was observed between the BPH and the PCA without bone metastases groups. Serum levels of ICTP were significantly higher in the PCA with (10.4 +/- 10.3 ng/ml) and without bone metastases groups (7.7 +/- 6.0 ng/ml) than in the BPH group (3.7 +/- 2.0 ng/ml). There was no significant difference between the PCA groups with and without bone metastases.
  
  
  CONCLUSIONS
  Serum PICP levels correlate well with results of bone scans, while serum ICTP levels increase in patients with PCA regardless of the presence of bone metastases.
authors.affiliation: Department of Urology, Dokkyo University School of Medicine, Mibu, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hosoya
authors.forename: K
authors.initials: K
authors.lastname: Arai
authors.forename: M
authors.initials: M
authors.lastname: Honda
authors.forename: S
authors.initials: S
authors.lastname: Sumi
authors.forename: K
authors.initials: K
authors.lastname: Yoshida
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000556:secondary*; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D001706:Biopsy; D001859:Bone Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000556:secondary*; D003094:Collagen / Q000097:blood*; D024042:Collagen Type I; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D010446:Peptide Fragments / Q000097:blood*; D010455:Peptides / Q000097:blood*; D011347:Procollagen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000473:pathology; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology*; D011863:Radioimmunoassay; D011877:Radionuclide Imaging
chemical_list: D014408:Biomarkers, Tumor; D024042:Collagen Type I; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; C042813:procollagen type I carboxy terminal peptide; D003094:Collagen